<- Go Home
CinCor Pharma, Inc.
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc.
Market Cap
$1.3B
Volume
232.3K
Cash and Equivalents
$292.6M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$43.15
52 Week Low
$10.53
Dividend
N/A
Price / Book Value
2.45
Price / Earnings
-9.39
Price / Tangible Book Value
2.45
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$82.5M
Return on Equity
26.91%
Return on Assets
-15.25
Cash and Short Term Investments
$522.5M
Debt
N/A
Equity
$518.9M
Revenue
N/A
Unlevered FCF
-$49.5M
Sector
Pharmaceuticals
Category
N/A